Prevalence and characteristics of hepatitis B and D virus infections among HIV-positive individuals in Southwestern Nigeria by Opaleye, Oluyinka Oladele et al.
Opaleye et al. Virol J           (2021) 18:20  
https://doi.org/10.1186/s12985-021-01493-4
RESEARCH
Prevalence and characteristics of hepatitis 
B and D virus infections among HIV-positive 
individuals in Southwestern Nigeria
Oluyinka Oladele Opaleye1†, Olusola Anuoluwapo Akanbi1,2†, Folakemi Abiodun Osundare1,2, Bo Wang2, 
Olufisayo Adesina2,3, Adeolu Sunday Oluremi1, Sola Thomas Sunday1, Abiodun Akeem Akindele1, 
Patrycja Klink2 and C. Thomas Bock2,4*
Abstract 
Background: Coinfections of HIV-positive individuals with Hepatitis B and D virus (HBV and HDV) are common and 
can be associated with rapid liver damage. Several antiretroviral drugs for HIV exhibit anti-HBV effect; however, the 
selection of HBV drug resistance mutations (DRMs) in individuals under HIV antiretroviral therapy (ART) has been 
reported but rarely in Nigeria. In this study the HBV/HDV prevalence and HBV DRMs in HIV-positive individuals in 
Southwestern Nigeria were assessed.
Methods: Plasma samples collected from 310 HIV-positive individuals including 295 ART-experienced and 15 ART-
naïve persons attending the HIV clinic in three south-western states of Nigeria between June 2017 and August 2017 
were analysed by ELISA for HBsAg and anti-HDV. The presence of HDV RNA and HBV DNA was analysed by (RT)-PCR 
followed by sequencing and phylogenetic analyses for genotyping. The HBV reverse transcription (RT) region was 
amplified and sequenced for the analysis of drug resistance mutations.
Results: Overall, 16.1% (n = 50/310) of the HIV-positive individuals were positive for HBsAg, most of which were ART-
experienced (94.0%; n = 47/50). From the 50 HBsAg-positive samples, 72.0% (n = 36/50) were positive for HBV DNA 
and 16.0% (n = 8/50) had detectable HDV RNA while 5.6% (n = 2/36) of the HBV-DNA positive samples had anti-HDV 
total antibodies. Sequences were available for 31/36 of the HBV DNA-positive and 3/8 HDV RNA-positive samples. 
HBV DNA-positive samples were characterised as HBV genotype E infections exclusively, while HDV genotype 1 was 
detected in the HDV RNA-positive samples. HBV DRMs V173L, L180M, S202I and M204V/I, which are associated with 
lamivudine resistance, were detected in 32.2% (n = 10/31) of the HBV DNA-positive samples. Most of these mutations 
(90.0%; n = 9/10) were present in the ART-experienced cohort.
Conclusions: This study indicates that HBV/HDV coinfections are common in HIV-positive individuals under ART in 
Nigeria. Furthermore, a high proportion of HBV DRMs which potentially compromise future treatment options were 
detected, underscoring the need for HBV screening prior to starting ART. Further studies should be performed to 
monitor a possible increase in the spread of HDV among populations at risk of HIV and HBV infections.
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Background
Due to shared routes of transmission, co-infection of HIV 
with hepatitis viruses is common worldwide and it is esti-
mated that 5–20% of the approximately 37 million people 
living with HIV are co-infected with HBV [1]. In Africa 
(Nigeria inclusive), HBV is hyper-endemic and HBV/HIV 
co-infections are highly prevalent [2]. Compared to HBV 
or HIV mono-infected individuals, co-infected individu-
als have a higher risk of impaired immunological recov-
ery and hepatotoxicity during antiretroviral treatment 
(ART) and a faster rate of progression to cirrhosis and 
hepatocellular carcinoma [3, 4].
The prevalence of HDV is about 5% among HBV carri-
ers however, rates between 3 and 30% have been reported 
in West Africa [5–7]. HDV co-infection increases the risk 
for hepatitis flares and chronic hepatic complications 
especially in individuals with HBV/HIV co-infection [8]. 
However, the impact of HDV infection on HIV/HBV co-
infected individuals is not well documented, especially in 
Nigeria where HDV is not routinely diagnosed.
Currently, six nucleoside analogues have been 
approved for the treatment of chronic HBV infection, all 
of which are inhibitors of the reverse transcriptase (RT) 
of HBV [9] and some of them (3TC and TDF/TAF) are 
also part of the first line regimen used for HIV ART [10]. 
Administration of these drugs in HIV-positive patients 
without knowledge of their HBV status can lead to the 
emergence of HBV drug resistance mutations (DRMs) 
and potentially limiting the treatment options avail-
able for the treatment of HBV [11]. Therefore, the World 
Health Organisation (WHO) [12] has recommended that 
all HIV-infected patients should be tested for the pres-
ence of HBV prior to initiation of therapy [12], but this 
is rarely done in Nigeria and some parts of sub-Saharan 
Africa due to high costs or partly due to neglect of the 
disease and concentration on HIV treatment [13, 14].
The HBV status of most HIV-infected individuals 
remains unknown, and first line ART regimen for HIV 
contains zidovudine (AZT), lamivudine (3TC) and nevi-
rapine (NVP) in Nigeria (https ://www.who.int/hiv/pub/
guide lines /niger ia_art.pdf ). As a result of the low genetic 
barrier to resistance of 3TC, [15] the risk for the emer-
gence of drug resistant HBV strains is increased. Moreo-
ver, studies have shown that HBV mutations can occur 
even in the absence of 3TC therapy in drug-naïve HBV 
carriers, thereby contributing to the rapid development 
of drug resistance [16].
Thus, knowledge of HBV and HDV status among 
HIV-infected patients is important for adequate clinical 
monitoring and selection of ART regimen. This study 
was carried out to investigate the prevalence and geno-
type distribution of HBV and HDV in HIV-positive 
individuals in Southwestern Nigeria. Furthermore, the 
presence of HBV DRMs in ART-experienced and naïve 
HIV-infected individuals was analysed.
Methods
Study population
Plasma samples were randomly collected from 310 HIV-
positive individuals including 295 ART-experienced 
and 15 ART-naive HIV-positive persons. The samples 
were collected from the HIV clinics of Adeoyo hospital, 
Ibadan, Oyo state (82 samples) and LAUTECH teach-
ing hospital, Osogbo, Osun state (100 samples) and Offa, 
Kwara state (128 samples) both located in the southwest-
ern region of Nigeria. Samples were collected between 
June and August 2017. Informed consent of each partici-
pant was obtained before sample collection and the study 
was approved by the Ethical review board of LAUTECH 
Teaching Hospital, Osogbo, Nigeria. Samples were stored 
at − 80  °C until testing and all laboratory analyses were 
carried out at the Robert Koch Institute, Berlin, Germany.
HBV and HDV serology
Qualitative detection of HBsAg was performed using the 
Wantai HBsAg ELISA (Wantai Hepatitis B virus Diag-
nostics, China). Anti-HDV antibodies were analysed 
using the ETI-AB-DELTAK-2 enzyme immune-assay 
(anti-HD; DiaSorin Limited, Germany) for the qualita-
tive determination of total antibodies to hepatitis delta 
antigen. All tests were performed following the manufac-
turer’s instructions.
Nucleic acid extraction and PCR amplification
Total viral nucleic acids were extracted from 140  μl of 
plasma using the QIAamp MinElute Virus Spin Kit (Qia-
gen, Hilden, Germany) using the QIACUBE automated 
system (Qiagen, Hilden, Germany). Nucleic acids were 
eluted in 60 µl of nuclease-free elution buffer and stored 
at − 80  °C until use. For HBV genotyping, the partial 
HBV S-gene was amplified using nested PCR as previ-
ously described [17]. HBV DRMs were detected by the 
amplification of a partial coding region of the HBV RT-
region designated for antiviral resistance using nested 
PCR followed by population-based Sanger sequencing.
HDV was genotyped by HDV-specific nested RT-PCR 
using primers designed for the amplification of a highly 
conserved region of the HDV genome (LHDAg region, 
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nucleotide 888 to 1122) and sequencing as previously 
described [6, 18]. All PCR products were analysed on 
1.5% Agarose gels.
HBV quantitative polymerase chain reaction
The HBV viral load was determined by quantitative 
real-time PCR (qPCR) using the Roche Lightcycler 480 
(Roche, Mannheim, Germany) as described previously 
using primers in the region of overlap between the 
S-gene and P-gene resulting in a product of approxi-
mately 89  bp in size [17]. Absolute quantification of 
HBV genomes was carried out and expressed in cop-
ies per ml of plasma. HBV plasmid DNA was used to 
generate a standard curve following a serial 10-fold 
dilution. Our quantitative HBV-specific PCR assays 
were routinely standardized using the WHO standard 
(NIBSC code: 97/750). In addition, the detection of 
HBV DNA by real-time PCR in our laboratories was 
successfully validated by Quality Control for Molecular 
Diagnostics (QMCD, which is an independent Interna-
tional External Quality Assessment (EQA) / Proficiency 
Testing (PT) organization) round robin tests.
Sequencing and phylogenetic analyses
Prior to sequencing, PCR amplicons were purified using 
ExoSAP-IT (Thermo Fischer Scientific, USA). Cycle-
sequencing was performed on an ABI 3500 automated 
genetic analyser (Applied Biosystems Inc., Foster city, 
California, USA) with 1.0  μl of the BigDye® Termina-
tor v3.1 Ready Reaction Mix (Applied Biosystems Inc., 
Foster city, California, USA) and 0.5 μl of each primer 
as described previously [6, 17]. Consensus sequences 
were generated by alignment of both sequenced strands 
with forward and reverse primers and subsequent 
manual edition to evaluate ambiguities using Geneious 
10.0.5 (Biomatters Limited, Auckland, New Zealand). 
A Neighbor-Joining tree method with the maximum 
likelihood approach was constructed from consensus 
sequences using the MEGA 7 software version 7.0.26 
[19]. For HBV phylogeny, representative reference 
sequences representing the HBV genotypes A-H and 
for HDV, reference sequences for genotypes 1–8 were 
randomly selected and retrieved from GenBank. Muta-
tion analysis and prediction was done using BioEdit 
version 7.2.5. (http://www.mbio.ncsu.edu/BioEd it/
bioed it.html), the geno2pheno [hbv] 2.0 online tool 
(https ://hbv.geno2 pheno .org/) and the HBVSeq tool of 
the Stanford HBV reverse transcriptase sequence vari-
ant database (HBVrtDB) [20]; https ://hivdb .stanf ord.
edu/HBV/HBVse q/devel opmen t/HBVse q.html) online 
tool.
Statistical analysis
Statistical analyses were done by Fischer’s exact tests 
with SPSS version 20.0.1 for Windows. A p value < 0.05 
was considered to be statistically significant.
Results
Characteristics of the study population
The study population included 310 HIV-positive indi-
viduals with a median age of 40 years (range 4–73 years) 
and a median CD4 count of 459 cells/ml (range 6–2028 
cells/ml). Of these, 63.2% (n = 196/310) were females 
while 36.8% (n = 114/310) were males. Most of the 
study participants (95%; n = 295/310) were on HIV 
ART (median age = 40 years; range 8–60 years; median 
CD4 count 462 cells/ml; range 2–2028) with combi-
pack (a fixed-dose formulation of AZT + 3TC + NVP). 
Only5% (n = 15/310) of the study participants were 
ART-naïve (median age = 40 years; range 8–73; median 
CD4 count = 392 cells/ml; range 219–960).
Prevalence of HBV and HDV infections in HIV‑positive 
individuals
In total, 16.1% (50/310) of the HIV-positive individu-
als were positive for HBsAg with a prevalence of 15.9% 
(n = 47/295) in the ART-experienced cohort and 20% 
(n = 3/15) in the ART-naïve cohort (Table  1). The 
majority of individuals tested positive for HBsAg (94%; 
n = 47/50) were ART-experienced.
HBV DNA was detected in 72% (n = 36/50) of the 
HIV/HBsAg-positive individuals, with 97% (n = 35/36) 
being ART-experienced. The median HBV viral 
load was slightly lower in individuals being ART-
experienced in comparison to ART-naïve individu-
als (1.44 × 105 vs. 4.36 × 106  copies/ml) as well as the 
median CD4 counts (497.85  cells/ml vs. 243  cells/ml) 
in the ART-experienced and the ART-naïve individuals, 
respectively (Table 1).
Among HBV DNA-positive samples, anti-HDV anti-
bodies were detected in 5.6% (n = 2/36), all of which 
were HDV RNA-negative. 16.0% (n = 8/50) of the 
HBsAg-positive samples were positive for HDV RNA 
but negative for anti-HDV.
HBV and HDV genotyping
To determine the HBV genotypes in the study cohort, 
the HBV isolates from this study were genotyped by 
sequencing and phylogenetic analyses of a partial 
region of the S and/or P genes. Of the 36 HBV DNA-
positive samples 31 (86.1%) were successfully geno-
typed and all belonged to HBV genotype E (Fig. 1).
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Three of eight (37.5%) HDV RNA-positive samples 
could be successfully sequenced and showed HDV gen-
otype 1 (Fig. 2).
HBV drug resistance mutations
HBV DRMs were detected in 32.3% (n = 10/31) of 
the successfully sequenced HBV DNA-positive sam-
ples (Table  2). Amino acid substitutions were detected 
in the following frequency: rtM204V/I (9/31; 29.0%), 
rtL180M (8/31; 25.8%), rtV173L (7/31; 22.5%). All of 
these substitutions are associated with a reduced sus-
ceptibility to lamivudine. In total, DRMs were detected 
in 10 individuals, of which 9 (90%) were ART-expe-
rienced and were treated with a fixed combination of 
zidovudine, lamivudine, and nevirapine (AZT/3TC/
NVP). No single mutation was detected while all 
amino acid substitutions were detected in combina-
tions as rtL180M + rtV173L + rtM204V (n = 7/10), 
rtV173L + rtM204V (1/10), rtL180M + rtM204I 
(1/10), and rtL180M + rtM204V + rtS202I (1/10). One 
of the individuals showing the DRM combination 
rtM204V/I + rtL180M + rtS202I was an ART-naive HIV/
HBV/HDV-positive patient (Table 2; Fig. 3).
Discussion
Co-infection of HBV and HDV with HIV is still a major 
public health problem in Sub-Saharan Africa due to the 
high endemicity of these virus infections and the more 
severe clinical outcomes of coinfections in comparison to 
the mono-infections [4, 6, 21]. A vaccination programme 
against HBV (effective also for HDV) has been intro-
duced in Nigeria since 2004; however, the prevalence of 
HBV remains high (10–15% [6, 22] compared to a prev-
alence of 20–25% before the advent of the vaccination 
[23]). The prevalence of HDV is 9% while earlier preva-
lence data are not available from Nigeria [6]. According 
to the recommendation of the WHO on HIV-ART in 
adults and adolescents, HBsAg testing should be done 
before the initiation of ART [24, 25]; however, this is not 
the rule in most low-income countries including Nigeria.
In this study among HIV-positive individuals in South-
western Nigeria, 16.1% (n = 50/310) were HBsAg posi-
tive, of which 72% (n = 36/50) corresponding to 11.6% 
overall (n = 36/310) were also positive for HBV DNA. The 
prevalence of HBsAg observed in this study is high com-
pared to previous reports from Africa, like South Africa 
with 7.6% [26], 1.1% in Mali [27], and 6.5% in south east-
ern Nigeria [28]; contrarily it is lower than other reports 
from southwestern Nigeria with a HBsAg prevalence of 
28.4% [29] and 21% in Cameroon [30]. The relatively high 
HBsAg prevalence observed in this study indicates that 
HBV is highly endemic in southwestern Nigeria and may 
possibly be a consequence of increasing drug resistant 
HBV strains circulating in this region [31].
Of the 50 HBsAg positive individuals, 16.1% (n = 8/50) 
were positive for HDV RNA. The prevalence of HDV 
Table 1 Characteristics of study participants
+ve, positive
HIV (ART‑experienced) HIV(ART‑naive) Total
Patient number 295 15 310
Median age (range) years 40 (4–60) 40 (8–73) 40 (4–73)
Gender
Female, n (%) 184 (62.4) 12 (80) 196 (63)
Male, n (%) 111 (37.6) 3 (20) 114 (37)
Median CD4 cell count (range) cells/ml 462 (6–2028) 392 (219–960) 459 (6–2028)
HBsAg +ve, n (%) 47 (15.9) 3 (20) 50 (16.1)
HBV DNA, n (%) 35 (11.9) 1 (6) 36 (11.6)
Median HBV viral load (copies/ml) 1.44 × 105 4.36 × 106 1.39 × 105
Anti-HDV, n (%) 2 (0.7) 0 (0) 2 (0.6)
HDV-RNA, n (%) 7 (2.4) 1 (6) 8 (2.6)
(See figure on next page.)
Fig. 1 Phylogenetic analysis of the HBV isolates circulating among the HIV/HBV co-infected population in this study. The evolutionary history was 
inferred by using the Maximum Likelihood method based on the Tamura-Nei model. The tree with the highest log likelihood (-2314.93) is shown. 
The percentage of trees in which the associated taxa clustered together is shown next to the branches. The isolates (denoted by NG-HBV) were 
analysed with respect to reference sequences retrieved from GenBank which are designated by their respective accession numbers along with 
their HBV genotypes/subgenotypes. HBV sequences of the isolates from this study are available at NCBI GenBank database (Acc. No.:MK239481–
MK239512)
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in this study is higher than the reported global HDV 
prevalence of 5% [32] and a recent report showing 9% 
HDV prevalence in the general population in South-
western Nigeria [6]. The high HDV prevalence in our 
study may be due to the analysed study cohort. Since 
HIV and HBV share the same transmission routes, co-
infection is common and might explain why the HBV 
and HDV prevalence is higher in this group than in the 
general population. In this study, only HDV genotype 1 
was detected and this agrees with previous reports which 
show that HDV-1 is ubiquitous and has been previously 
identified also in southwestern Nigeria [6]. Notably, we 
found that all HDV RNA positive samples were negative 
for anti-HDV ELISA which is probably due to the lower 
sensitivity of the anti-HDV ELISA in comparison to the 
PCR assay [6].
Liver disease due to HDV is known to progress faster 
in HIV-positive individuals independent of success-
ful ART [33]. In this study, characteristics such as HBV 
viral load and CD4 cell count did not significantly dif-
fer between the ART-experienced and the ART-naïve 
cohort. Furthermore, detection of antibodies against the 
delta antigen did not seem to correspond with molecular 
detection of HDV RNA. We therefore would recommend 
that samples tested negative by anti-HDV ELISA, should 
be retested by molecular methods especially in high risk 
groups.
In the past decade a number of new treatment options 
and regimens for HIV infection have been developed 
pioneering the control of the HIV infection and progres-
sion [10]. Nowadays also low-income countries like Nige-
ria have access to new and highly effective antiretroviral 
drugs (ARVs) but the old drugs which have a low barrier 
to resistance are still in use and widely distributed. There 
are a number of approved ARVs usually used as combi-
nation therapy including nucleoside reverse transcriptase 
inhibitors (NRTI), non-nucleoside reverse transcriptase 
inhibitors (NNRTI), protease inhibitors (PI), entry inhibi-
tors, and HIV integrase inhibitors (INI). Tenofovir (TDF/
TAF) and lamivudine (3TC), both NRTIs are also effec-
tive for the control of HBV replication and are recom-
mended for the treatment of chronic HBV infection.
Antiviral drug resistance has been described for HBV 
and HIV and the selection of HBV DRMs in patients 
co-infected with HIV under ART with nucleoside 
analogues have been previously reported [3, 24]. 
Amino acid (aa) substitutions found in this study 
include rtL180M, rtV173L, rtM204V/I among indi-
viduals on ART however, in one drug-naïve individ-
ual, aa substitutions L180M, M204V and S202I have 
also been detected. This drug-naïve individual might 
have been infected with a drug resistant HBV strain 
in circulation or selected the mutation due to fac-
tors other than antiviral therapy pressure. Primary aa-
substitution rtM204V was the most common in this 
study, conferring lamivudine-like resistance which 
has been reported previously to emerge at an annual 
rate of 15–20% in HIV-1/HBV co-infected individuals 
in developed countries [24]. Our finding implies that 
drug resistant HBV-strains are in circulation in Nige-
ria, which may have originated from ART-patients and 
may also be transmitted to susceptible individuals. 
Here, we found a high prevalence of resistance muta-
tions to nucleoside analogues and predominantly muta-
tions usually selected by lamivudine (rtL180M (25%; 
n = 9/36), rtV173L (22.2%), n = 8/36; rtM204V/I (27.8%; 
n = 10/36) and rtS202I (2.8%; n = 1/36) (Table 2) in the 
HIV/HBV co-infected individuals collectively. Addi-
tionally, we detected HBV DRMs also in HIV/HBV/
HDV co-infected individuals.
The control of HBV infections with antivirals has been 
reported to avert liver disease progression in most of 
HIV co-infected patients, however, the emergence of 
drug resistance and lack of satisfactory treatment options 
for HDV-infection remains a major threat [34].
It has been recommended that HBV screening should 
be carried out in HIV patients at baseline before com-
mencement of ART therapy however, our findings dem-
onstrates that not only baseline HBV testing is important 
in HIV-infected populations but also HBV resistance and 
HDV testing may be necessary before initiation of ART 
to ensure a well-adapted and more personalized therapy 
option.
The limitations to this study are the relatively small 
sample size and the inability to follow-up the par-
ticipants. We were also not able to perform additional 
serological tests due to limited sample volume, e.g. to 
determine anti-HBc (core) IgM of HBsAg-positive sam-
ples to differentiate chronic HBV from acute cases as 
they may behave differently.
Fig. 2 Phylogenetic analysis inferred from distance analysis (Kimura 2 parameters model) using neighbour-joining bootstrap 1000 replicate 
reconstruction from HDV sequences of the Nigerian HDV isolates in this study (highlighted in boldface and designated as NIG/HDV and numbers) 
and the corresponding region of reference sequences showing that the Nigerian HDV isolates clustered in the HDV genotype 1 branch. The 
Nigerian HDV sequences were compared to HDV reference sequences gathering the 8 HDV genotypes (HDV1 to HDV8). The numbers at the nodes 
indicate bootstrapping values. The bar represents nucleotide substitutions per position. HDV sequences of the patient isolates are available at NCBI 
GenBank database (Acc. No.:MK239513–MK239515)
(See figure on next page.)
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Conclusions
Coinfections of HIV-positive individuals with Hepati-
tis B and D viruses are common especially in regions 
where these virus infections are endemic. Coinfection of 
HIV with HBV and additionally HDV can be associated 
with more severe liver disease than mono-infection with 
HBV. HIV-ART will also affect HBV since HBV DRMs 
can occur. Accordingly, this study indicates that HBV/
HDV coinfections are common in HIV-positive individu-
als under ART in Nigeria and the prevalence of viremic 
HDV is high in HIV-positive persons in Nigeria (16.1%). 
Moreover, a high number of HBV drug resistance muta-
tions were detected underscoring the need for HBV 
screening prior to starting ART.
Abbreviations
HIV: Human immunodeficiency viruses; HBV: Hepatitis B virus; HDV: Hepatitis D 
virus (delta virus); DRM: Drug resistance mutation; ART : Anti-retroviral therapy; 
TDF/TAF: Tenofovir alafenamid; 3TC: Lamivudine; rt: Reverse transcription.
Acknowledgements
We thank the medical staff of the HIV clinics of Adeoyo hospital, Ibadan, Oyo 
state and LAUTECH teaching hospital, Osogbo, Osun state and Offa, Kwara 
state for their assistance during collection of the samples. We are grateful for 
the excellent technical assistance of Steffen Zander and Hannes Jarmuth (RKI).
Authors’ contributions
OOO, OAA and CTB initiated, participated in conception and designed of the 
study. ASO, STS and AAA collected samples. OOO, OAA and FAO; performed 
the experiments. OAA, BW, OOO and OA analyzed and interpreted the data. 
OAA, OOO, PM and CTB prepared the manuscript. All authors read and 
approved the final manuscript.
Funding
Open Access funding enabled and organized by Projekt DEAL. This work was 
supported by a grant from the German Federal Ministry of Health (BMG) with 
regard to a decision of the German Bundestag by the Federal Government 
(NiCaDe-project grant No: ZMVI1-2519GHP711 / D81667). O.O.O., F.A.O, and 
O.A. are funded by a sub-project of the Global Health Protection Programme 
(GHPP) supported by the German Federal Ministry of Health on the basis of a 
decision by the German Bundestag, the Partnership in Postgraduate Education 
(PPE), Robert Koch Institute, Berlin, Germany. O.A.A. is funded by the German 
Academic Exchange Service (DAAD), Bonn, Germany. B.W. is funded by the 
China Scholarship Council (CSC), Beijing, China. The funders BMG, CSC, DAAD, 
and GHPP/PPE had no role in study design, data collection and interpretation, 
Table 2 Characteristics of individuals with HBV drug resistance mutations
Combipack, zidovudine + lamivudine + nevirapine (AZT/3TC/NVP); P-region, Hbv polymerase region (reverse transcriptase)
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Fig. 3 Representative HBV-amino acid (AA) sequences of the HIV/HBV coinfected individuals with DRMs aligned with HBV reference sequence 
X75657. HBV-AA sequences spanning the P-region of HBV from aa 120 to aa 240 showing patient-specific HBV isolates
Page 9 of 10Opaleye et al. Virol J           (2021) 18:20  
or the decision to submit the work for publication. The content is the responsi-
bility only of the authors and does not represent the views of the funders.
Availability of data and materials
All data generated or analysed during this study are included in this published 
article.
Ethics approval and consent to participate
Informed consent of each participant was obtained before sample collection 





The authors declare that they have no competing interests.
Author details
1 Department of Medical Microbiology and Parasitology, Ladoke Akintola 
University of Technology, Ogbomoso, Oyo State, Nigeria. 2 Division of Viral 
Gastroenteritis and Hepatitis Pathogens and Enteroviruses, Department 
of Infectious Diseases, Robert Koch Institute, Berlin, Germany. 3 Department 
of Microbiology, Obafemi Awolowo University, Ile Ife, Osun State, Nigeria. 
4 Institute of Tropical Medicine, University of Tuebingen, Tuebingen, Germany. 
Received: 1 November 2019   Accepted: 8 January 2021
References
 1. Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-
hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. 
Aids. 2017;31(15):2035–52.
 2. Assih M, Ouattara AK, Diarra B, Yonli AT, Compaore TR, Obiri-Yeboah 
D, Djigma FW, Karou S, Simpore J. Genetic diversity of hepatitis 
viruses in West-African countries from 1996 to 2018. World J Hepatol. 
2018;10(11):807–21.
 3. Chun HM, Mesner O, Thio CL, Bebu I, Macalino G, Agan BK, Bradley 
WP, Malia J, Peel SA, Jagodzinski LL, et al. HIV outcomes in Hepatitis B 
virus coinfected individuals on HAART. J Acquir Immune Defic Syndr. 
2014;66(2):197–205.
 4. Hønge BL, Jespersen S, Medina C, Té DS, da Silva ZJ, Lewin S, Østergaard 
L, Erikstrup C, Wejse C, Laursen AL, et al. Hepatitis B and delta virus 
are prevalent but often subclinical co-infections among HIV infected 
patients in Guinea-Bissau, West Africa: a cross-sectional study. PLoS ONE. 
2014;9(6):e99971.
 5. World Health Organization (WHO). Global hepatitis report 2017. https ://
www.who.int/hepat itis/publi catio ns/globa l-hepat itis-repor t2017 /en/
 6. Opaleye OO, Japhet OM, Adewumi OM, Omoruyi EC, Akanbi OA, Oluremi 
AS, Wang B, Tong HV, Velavan TP, Bock CT. Molecular epidemiology of 
hepatitis D virus circulating in Southwestern Nigeria. Virol J. 2016;13:61.
 7. Lunel-Fabiani F, Mansour W, Amar AO, Aye M, Le Gal F, Malick FZF, Baïdy 
L, Brichler S, Veillon P, Ducancelle A, et al. Impact of hepatitis B and delta 
virus co-infection on liver disease in Mauritania: a cross sectional study. J 
Infect. 2013;67(5):448–57.
 8. Katwesigye E, Seremba E, Semitala F, Ocama P. Low sero-prevalence of 
hepatitis delta antibodies in HIV/ hepatitis B co-infected patients attend-
ing an urban HIV clinic in Uganda. Afr Health Sci. 2016;16(4):1089–93.
 9. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, 
Zoulim F, Tacke F. EASL 2017 Clinical Practice Guidelines on the manage-
ment of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.
 10. Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy 
JF, Mugavero MJ, Sax PE, Thompson MA, et al. Antiretroviral drugs 
for treatment and prevention of HIV infection in adults: 2016 recom-
mendations of the International Antiviral Society-USA Panel. JAMA. 
2016;316(2):191–210.
 11. Warner N, Locarnini S. Mechanisms of hepatitis B virus resistance devel-
opment. Intervirol. 2014;57(3–4):218–24.
 12. World Health Organization (WHO). Guidelines for the prevention, care 
and treatment of persons with chronic hepatitis B infection. 2015. https ://
www.who.int/hiv/pub/hepat itis/hepat itis-b-guide lines /en/
 13. Belyhun Y, Maier M, Liebert UG. HIV therapy with unknown HBV status is 
responsible for higher rate of HBV genome variability in Ethiopia. Antivir 
Ther. 2017;22(2):97–111.
 14. Chambal LM, Samo Gudo E, Carimo A, Corte Real R, Mabunda N, Maueia 
C, Vubil A, Zicai AF, Bhatt N, Antunes F. HBV infection in untreated HIV-
infected adults in Maputo, Mozambique. PLoS ONE. 2017;12(7):e0181836.
 15. Oreagba IA, Usman SO, Olayemi SO, Oshikoya KA, Opanuga O, Adey-
emo TA, Lesi OA, Dodoo AN, Akanmu AS. Pharmacoepidemiology of 
antiretroviral drugs in a teaching hospital in Lagos. Nigeria Ghana Med J. 
2014;48(4):194–203.
 16. Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ. 
Mutations associated with lamivudine-resistance in therapy-naive hepa-
titis B virus (HBV) infected patients with and without HIV co-infection: 
implications for antiretroviral therapy in HBV and HIV co-infected South 
African patients. J Med Virol. 2007;79(11):1650–4.
 17. Oluyinka OO, Tong HV, Bui Tien S, Fagbami AH, Adekanle O, Ojurongbe 
O, Bock CT, Kremsner PG, Velavan TP. Occult hepatitis B virus infection in 
nigerian blood donors and hepatitis B virus transmission risks. PLoS ONE. 
2015;10(7):e0131912-e132012.
 18. Sy BT, Ratsch BA, Toan NL, Song LH, Wollboldt C, Bryniok A, Nguyen 
HM, Luong HV, Velavan TP, Wedemeyer H, et al. High prevalence and 
significance of hepatitis D virus infection among treatment-naïve HBsAg-
positive patients in Northern Vietnam. PLoS ONE. 2013;8(10):e78094–194.
 19. Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics 
analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33(7):1870–4.
 20. Rhee SY, Margeridon-Thermet S, Nguyen MH, Liu TF, Kagan RM, Beggel 
B, Verheyen J, Kaiser R, Shafer RW. Hepatitis B virus reverse transcriptase 
sequence variant database for sequence analysis and mutation discovery. 
Antiviral Res. 2010;88(3):269–75.
 21. Noubiap JJN, Nansseu JRN, Ndoula ST, Bigna JJR, Jingi AM, Fokom-
Domgue J. Prevalence, infectivity and correlates of hepatitis B virus infec-
tion among pregnant women in a rural district of the Far North Region of 
Cameroon. BMC Public Health. 2015;15(1):454.
 22. Nongo B, Agida T, Oghenebuk U, Yunusa T. Seroprevalence of hepatitis 
B virus among antenatal attendees at the University of Abuja Teaching 
Hospital, Nigeria. An Niger Med. 2016;10(2):58–62.
 23. Musa BM, Bussell S, Borodo MM, Samaila AA, Femi OL. Prevalence of 
hepatitis B virus infection in Nigeria, 2000–2013: a systematic review and 
meta-analysis. Niger J Clin Pract. 2015;18(2):163–72.
 24. Gu L, Han Y, Li Y, Zhu T, Song X, Huang Y, Yang F, Guan S, Xie J, Gohda 
J, et al. Emergence of lamivudine-resistant HBV during antiretroviral 
therapy including lamivudine for patients coinfected with HIV and HBV in 
China. PLoS ONE. 2015;10(8):e0134539.
 25. World Health Organization (WHO). Consolidated guidelines on the use of 
antiretroviral drugs for treating and preventing HIV infection. Recommen-
dations for a public health approach; 2nd ed.; 2016. https ://www.who.int/
hiv/pub/arv/arv-2016/en/
 26. King J, Hagemeister DT. Hepatitis B co-infection in HIV-infected patients 
receiving antiretroviral therapy at the TC Newman Anti Retroviral Treat-
ment Clinic in Paarl, Western Cape. South Afr J HIV Med. 2016;17(1):336.
 27. Tounkara A, Sarro YS, Kristensen S, Dao S, Diallo H, Diarra B, Noumsi 
TG, Guindo O. Seroprevalence of HIV/HBV coinfection in Malian blood 
donors. J Int Assoc Phys AIDS Care. 2009;8(1):47–51.
 28. Okeke TC, Obi SN, Okezie OA, Ugwu EO, Akogu SP, Ocheni S, Ezenyeaku 
CC. Coinfection with hepatitis B and C viruses among HIV positive preg-
nant women in Enugu south east. Nigeria Niger J Med. 2012;21(1):57–60.
 29. Balogun TM, Emmanuel S, Ojerinde EF. HIV, Hepatitis B and C viruses’ 
coinfection among patients in a Nigerian tertiary hospital. Pan Afr Med J. 
2012;12:100.
 30. Mbougua JBT, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, Calmy A, 
Gwet H, Koulla-Shiro S, Ducos J, Mpoudi-Ngolé E, et al. Hepatotoxic-
ity and effectiveness of a Nevirapine-based antiretroviral therapy in 
HIV-infected patients with or without viral hepatitis B or C infection in 
Cameroon. BMC public health. 2010;10:105.
 31. Mado S, Idris H, Abdullahi S, Musa S. Probable lamivudine-resistant hepa-
titis B infection in children: a case report involving two Nigerian siblings 
at Ahmadu Bello University Teaching Hospital, Shika, Zaria. Sub-Saharan 
Afric J Med. 2017;4(3):87–90.
Page 10 of 10Opaleye et al. Virol J           (2021) 18:20 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 32. Andernach IE, Leiss LV, Tarnagda ZS, Tahita MC, Otegbayo JA, Forbi JC, 
Omilabu S, Gouandjika-Vasilache I, Komas NP, Mbah OP, Muller CP. Char-
acterization of hepatitis delta virus in sub-Saharan Africa. J Clin Microbiol. 
2014;52(5):1629–36.
 33. Castellares C, Barreiro P, Martin-Carbonero L, Labarga P, Vispo ME, Casado 
R, Galindo L, Garcia-Gasco P, Garcia-Samaniego J, Soriano V. Liver cirrhosis 
in HIV-infected patients: prevalence, aetiology and clinical outcome. J 
Viral Hepat. 2008;15(3):165–72.
 34. Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L, Mendoza CD, Arias 
A, Barreiro P, Peña JM, Labarga P. Dual antiretroviral therapy for HIV infec-
tion. Exp Opin Drug Saf. 2017;16(8):923–32.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
